The left navigation bar requires Javascript to be enabled. Please enable Javascript on your browser or
use the Site Map
to navigate.
Contact Newsroom
Podcast
RSS
These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information.
EMEND® (fosaprepitant dimeglumine) for Injection
Full Prescribing Information
Patient Product Information
29 Jan 2008
FDA Approves EMEND® (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy
FOSAMAX® (alendronate sodium tablets)
13 Dec 2007
[Updated on December 13th, 2007] Statement by Merck & Co., Inc., Regarding the Fracture Intervention Trial (FIT) with FOSAMAX® (alendronate sodium) and Incidence of Atrial Fibrillation
Gardasil® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
Full Prescribing Information
Patient Product Information
19 Mar 2008
Supplemental Application for GARDASIL®, Merck's Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
05 Nov 2007
New Data Presented on GARDASIL®, Merck's Cervical Cancer Vaccine, in Women Through Age 45
ISENTRESS™ (raltegravir)
Full Prescribing Information
Patient Product Information
06 Feb 2008
Merck's ISENTRESS® (raltegravir) Tablets in Combination with other Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and Increased CD4 Cell Counts Through 48 Weeks of Therapy in Treatment-Experienced Adults
Janumet™ (sitagliptin/metformin HCl) tablets
Full Prescribing Information
Patient Product Information
24 Apr 2008
Two Merck Medicines Recommended for Approval in the European Union
MEVACOR® (lovastatin)
Full Prescribing Information
25 Jan 2008
Merck Receives Not Approvable Letter from FDA for OTC MEVACOR® (lovastatin) 20 mg
13 Dec 2007
FDA Advisory Panel Recommends Against Approval of Merck's NDA for Non-prescription MEVACOR® (lovastatin) 20 mg
PedVax HIB® (haemophilus b conjugate vaccine [meningococcal protein conjugate])
Full Prescribing Information
12 Dec 2007
Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB® and COMVAX®
RotaTeq® (rotavirus vaccine, live, oral, pentavalent)
Full Prescribing Information
Patient Product Information
03 Dec 2007
Merck's ROTATEQ® Reduced Hospitalizations and Emergency Department Visits Due to G9P1A[8] Rotavirus by 100 Percent as Shown by Post-hoc Analysis of Data
SINGULAIR® (montelukast)
Full Prescribing Information
Patient Product Information
27 Mar 2008
Merck Statement on the FDA Early Communication of an Ongoing Safety Review of Montelukast (SINGULAIR™)
VYTORIN™ (ezetimibe/simvastatin)
Full Prescribing Information
Patient Product Information
30 Mar 2008
Merck/Schering-Plough Pharmaceuticals Comments on Results of the ENHANCE Study
28 Mar 2008
Statement on IMPROVE-IT Study
25 Jan 2008
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
19 Nov 2007
Merck/Schering-Plough Pharmaceuticals Provides Update on ENHANCE Trial
top
Printer Friendly Page
Printer Friendly Page
